Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.

[1]  P. Kilmarx,et al.  Global epidemiology of HIV , 2009, Current opinion in HIV and AIDS.

[2]  John P. Moore,et al.  Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor. , 2007, Biochemistry.

[3]  M. McElrath,et al.  Initial Events in Establishing Vaginal Entry and Infection by Human Immunodeficiency Virus Type-1 , 2007, Immunity.

[4]  John P. Moore,et al.  Which Topical Microbicides for Blocking HIV-1 Transmission Will Work in the Real World? , 2006, PLoS medicine.

[5]  Hong Lu,et al.  Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates. , 2006, AIDS research and human retroviruses.

[6]  M. Lederman,et al.  Microbicides and other topical strategies to prevent vaginal transmission of HIV , 2006, Nature Reviews Immunology.

[7]  Robin Shattock,et al.  Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? , 2006, Nature Reviews Microbiology.

[8]  P. Klasse,et al.  How Do Viral and Host Factors Modulate the Sexual Transmission of HIV? Can Transmission Be Blocked? , 2006, PLoS medicine.

[9]  John P. Moore,et al.  Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion , 2005, Nature.

[10]  M. Hirsch,et al.  TAK-652, a Novel CCR5 Inhibitor, has Favourable Drug Interactions with other Antiretrovirals in Vitro , 2005, Antiviral therapy.

[11]  P. Clapham,et al.  Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density. , 2005, Antiviral research.

[12]  A. Haase.  Perils at mucosal front lines for HIV and SIV and their hosts , 2005, Nature Reviews Immunology.

[13]  Dominique Schols,et al.  AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. , 2005, Biochemical pharmacology.

[14]  Lynn Morris,et al.  Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines , 2005, Journal of Virology.

[15]  Xiping Wei,et al.  Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.

[16]  M. Hirsch,et al.  TAK-220, a Novel Small-Molecule CCR5 Antagonist, Has Favorable Anti-Human Immunodeficiency Virus Interactions with Other Antiretrovirals In Vitro , 2005, Antimicrobial Agents and Chemotherapy.

[17]  P. Harrigan,et al.  Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. , 2005, The Journal of infectious diseases.

[18]  A. Trkola,et al.  Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors , 2005, Journal of Virology.

[19]  Eun-Young Kim,et al.  Propagation and Dissemination of Infection after Vaginal Transmission of Simian Immunodeficiency Virus , 2005, Journal of Virology.

[20]  E. Sanders-Buell,et al.  Biologic and Genetic Characterization of a Panel of 60 Human Immunodeficiency Virus Type 1 Isolates, Representing Clades A, B, C, D, CRF01_AE, and CRF02_AG, for the Development and Assessment of Candidate Vaccines , 2005, Journal of Virology.

[21]  B. Gazzard,et al.  Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. , 2005, The Journal of infectious diseases.

[22]  Ronald G. Collman,et al.  Preferential Use of CXCR4 by R5X4 Human Immunodeficiency Virus Type 1 Isolates for Infection of Primary Lymphocytes , 2005, Journal of Virology.

[23]  Renate Kunert,et al.  Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.

[24]  John P. Moore,et al.  Urgently needed: a filter for the HIV-1 vaccine pipeline , 2004, Nature Medicine.

[25]  John P. Moore,et al.  The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. , 2004, AIDS research and human retroviruses.

[26]  Michael Greenberg,et al.  Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes , 2004, Nature Reviews Drug Discovery.

[27]  Wayne C Koff,et al.  HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.

[28]  Olson Wc,et al.  Resistance to HIV-1 entry inhibitors. , 2003 .

[29]  B. Cullen,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Replication in Primary Macrophages by Using Tat- or CCR5-Specific Small Interfering RNAs Expressed from a Lentivirus Vector , 2003, Journal of Virology.

[30]  John P. Moore,et al.  Inhibiting sexual transmission of HIV-1 infection , 2003, Nature Reviews Microbiology.

[31]  N. Meanwell,et al.  Biochemical and Genetic Characterizations of a Novel Human Immunodeficiency Virus Type 1 Inhibitor That Blocks gp120-CD4 Interactions , 2003, Journal of Virology.

[32]  S. A. Gallo,et al.  The HIV Env-mediated fusion reaction. , 2003, Biochimica et biophysica acta.

[33]  Lynn Morris,et al.  The CCR5 and CXCR4 Coreceptors Are Both Used by Human Immunodeficiency Virus Type 1 Primary Isolates from Subtype C , 2003, Journal of Virology.

[34]  John P. Moore,et al.  Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. , 2003, AIDS research and human retroviruses.

[35]  John P. Moore,et al.  Human Immunodeficiency Virus Type 1 Attachment, Coreceptor, and Fusion Inhibitors Are Active against both Direct and trans Infection of Primary Cells , 2003, Journal of Virology.

[36]  Q. Sattentau,et al.  Occupancy and mechanism in antibody-mediated neutralization of animal viruses. , 2002, The Journal of general virology.

[37]  Martin S. Hirsch,et al.  Anti-Human Immunodeficiency Virus Interactions of SCH-C (SCH 351125), a CCR5 Antagonist, with Other Antiretroviral Agents In Vitro , 2002, Antimicrobial Agents and Chemotherapy.

[38]  Bette T. Korber,et al.  Immune control of HIV: the obstacles of HLA and viral diversity , 2001, Nature Immunology.

[39]  A. Trkola,et al.  Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 , 2001, Journal of Virology.

[40]  D. Burton,et al.  Antibody and virus: binding and neutralization. , 2000, Virology.

[41]  John P. Moore,et al.  Will Multiple Coreceptors Need To Be Targeted by Inhibitors of Human Immunodeficiency Virus Type 1 Entry? , 1999, Journal of Virology.

[42]  Dan R. Littman,et al.  Use of Coreceptors Other Than CCR5 by Non-Syncytium-Inducing Adult and Pediatric Isolates of Human Immunodeficiency Virus Type 1 Is Rare In Vitro , 1998, Journal of Virology.

[43]  A. Trkola,et al.  Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Primary Isolates to Antibodies and CD4-Based Reagents Is Independent of Coreceptor Usage , 1998, Journal of Virology.

[44]  A. Trkola,et al.  Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism , 1997, Journal of virology.

[45]  K. Mayer,et al.  Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection. , 2006, The Journal of infectious diseases.

[46]  F. McCutchan,et al.  Global epidemiology of HIV , 2006, Journal of medical virology.

[47]  S. Hammer,et al.  Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. , 2004, JAMA.

[48]  W. Olson,et al.  Resistance to HIV-1 entry inhibitors. , 2003, Current drug targets. Infectious disorders.